| Patent application number | Description | Published |
|---|
| 20080206364 | Topical nitric oxide as a treatment of autoimmune diseases - The present invention relates to compositions and methods for treatment of a patient affected with an autoimmune disorder, and in an embodiment, a skin-related autoimmune disorder. The treatment involves the application of gaseous nitric oxide to an affected patient, and in an embodiment, to the skin of an affected patient. | 08-28-2008 |
| 20080287861 | Device and method for treatment of wounds with nitric oxide - Topical exposure of nitric oxide gas to wounds such as chronic non-healing wounds may be beneficial in promoting healing of the wound and in preparing the wound bed for further treatment and recovery. Nitric oxide gas may be used, for example, to reduce the microbial infection and burden on these wounds, manage exudate secretion by reducing inflammation, upregulate expression of endogenous collagenase to locally debride the wound, and regulate the formation of collagen. High concentration of nitric oxide ranging from about 160 to 400 ppm may be used without inducing toxicity in the healthy cells around a wound site. Additionally, exposure to the high concentration for a first treatment period reduces the microbial burden and inflammation at the wound site and increase collagenase expression to debride necrotic tissue at the wound site. After a first treatment period with high concentration of nitric oxide, a second treatment period at a lower concentration of nitric oxide preferably ranging from about 5-20 ppm may to provided to restore the balance of nitric oxide and induce collagen expression to aid in the closure of the wound. | 11-20-2008 |
| 20090056708 | DEVICE, SYSTEM AND METHOD FOR TARGETING AEROSOLIZED PARTICLES TO A SPECIFIC AREA OF THE LUNGS - The present invention is directed to the administration of aerosolized particles to specific area of the lungs, and in particular to the targeted delivery of aerosolized pharmaceutical formulations to a specific area of the lungs. More specifically, the present invention relates to devices and methods for depositing aerosolized particles to a specific area of the lungs by regulating aerosolizing parameters of the device. The present invention also relates to devices, systems and methods for disease management, where the aerosolizing parameters are adjusted based on monitoring at least one health parameter. | 03-05-2009 |
| 20090107497 | Method and device to prevent ventilator acquired pneumonia using nitric oxide - A respiratory assist device and method for the prevention of ventilator acquired pneumonia in a patient is described. The respiratory assist device administers nitric oxide to the oropharyngeal area in order to decontaminate or prevent the contamination of secretions that collect in the oropharyngeal area during intubation of the patient. The respiratory assist device and method may be adapted for use, for example, as an endotracheal tube or as a tracheotomy tube. | 04-30-2009 |
| 20100024818 | CLOSED SUCTION CATHETER ADAPTER WITH FLUSH ARRANGEMENT - A respiratory apparatus including an adapter assembly and a catheter assembly. The adapter assembly includes ventilator, respiratory, access, and flush ports. The access port includes a conduit defining a passageway. The flush port projects from the conduit and is fluidly open to the passageway at an outlet. The catheter assembly includes a catheter assembled to a fitting. The fitting includes a hub and a tube, with the tube defining an exterior surface, an interior surface forming a lumen, a circumferential groove in the exterior surface, and a plurality of apertures fluidly open to the lumen and the circumferential groove. The tube is sized to be slidably received within the passageway such that upon final assembly, a fluid pathway is formed between the flush port and a distal end of the catheter via the flush port outlet, the circumferential groove, the plurality of apertures, and the lumen. | 02-04-2010 |
| 20100024823 | VALVE ASSEMBLY FOR RESPIRATORY SYSTEMS - An adapter assembly including a manifold and a valve assembly. The valve assembly includes a seat and a valve body having a circular base and a wall. The wall extends from a trailing side of the base to form a dome-like shape terminating at an end at which a slit is formed, with the wall defining opposing sealing edges at the slit. The seat has an upper circumferential surface and a lower circumferential surface. The upper surface engages a leading side of the base, whereas the lower surface engages a trailing side. At least one of the upper and lower surfaces forms a segment of increased height. Upon final assembly, the valve body is disposed across a passageway of the manifold, with the slit providing a selectively openable path. A force imparted by the segment of increased height flexes the base and biases the sealing edges into engagement. | 02-04-2010 |
| 20100174210 | FLUID FLOW CONTROL APPARATUS AND PATIENT FLUID SAMPLING METHOD - A fluid flow control apparatus used in medical fluid sampling. The apparatus includes a valve assembly, first and second ports, and a cap. The valve assembly comprises a body rotatably assembled to a housing and defining a passageway and at least two recesses defined by an interior surface of the housing and the body which is formed separate from the passageway. The ports extend from the housing and are configured for connection to medical devices. The valve assembly is operable to interchangeably align the passageway and the recesses with the ports. Finally, the cap is connected to the housing, and forms an opening for coupling to a specimen container. | 07-08-2010 |
| 20100206309 | GAS FLOW REGULATING DEVICE - A gas flow regulating device including a housing assembly, an inlet tube assembly, and a biasing device. The housing assembly has a main housing, a valve seat body, and a distal plate forming an outlet orifice. The inlet tube assembly includes a proximal inlet end, a tube forming a lumen, and a flange, and is slidably disposed within the main housing, biased to an open state by the biasing device. The flange separates middle and constant pressure chambers within the housing assembly. The inlet tube assembly is transitionable to a closed state in response to pressure in the constant pressure chamber to generate a relatively constant flow rate of air exiting the device via the outlet orifice. | 08-19-2010 |
| 20100241019 | EXHALED BREATH CONDENSATE BIOMETRIC MARKER MEASUREMENT APPARATUS AND METHOD - The present invention includes an apparatus and a method for testing exhaled breath condensate for at least one biometric marker, including a substrate for collecting exhaled breath condensate, the substrate capable of being brought to a temperature below a dew point of vapor in exhaled breath, a collector for retaining the substrate and for receiving a biometric marker reagent. The invention may further include receiving exhaled breath in a collector, the collector comprising a substrate, the substrate being at a temperature below a dew point of vapor in exhaled breath, collecting the exhaled breath condensate on the substrate, and bringing a biometric marker reagent in contact with the substrate. | 09-23-2010 |
| 20110112468 | DEVICE AND METHOD FOR TREATMENT OF SURFACE INFECTIONS WITH NITRIC OXIDE - Topical exposure of nitric oxide gas to wounds such as chronic non-healing wounds may be beneficial in promoting healing of the wound and in preparing the wound bed for further treatment and recovery. Nitric oxide gas may be used, for example, to reduce the microbial infection and burden on these wounds, manage exudate secretion by reducing inflammation, upregulate expression of endogenous collagenase to locally debride the wound, and regulate the formation of collagen. High concentration of nitric oxide ranging from about 160 to 400 ppm may be used without inducing toxicity in the healthy cells around a wound site. Additionally, exposure to the high concentration for a first treatment period reduces the microbial burden and inflammation at the wound site and increase collagenase expression to debride necrotic tissue at the wound site. After a first treatment period with high concentration of nitric oxide, a second treatment period at a lower concentration of nitric oxide preferably ranging from about 5-20 ppm may to provided to restore the balance of nitric oxide and induce collagen expression to aid in the closure of the wound. | 05-12-2011 |
